Ono Venture Investment

Shunichiro Matsumoto, PhD, is the President and CEO and leads investment decisions from the South San Francisco office. He joined Ono in 2020 after serving as the president of Astellas Venture Management, where he was a board member for portfolio companies Mitobridge and Potenza Therapeutics. The investment team includes directors with PhD-level training in pharmaceutical sciences and medicinal chemistry, allowing scientific diligence to be conducted in-house.

OVI sources deals through its bi-coastal US presence in South San Francisco and Cambridge, placing PhD-trained investors directly in two of the world's densest biotechnology ecosystems. Team members draw on existing relationships from Ono Pharma's alliance-management and research-collaboration groups, and the firm actively pursues investments in startups whose science can produce novel drug targets or platforms synergistic with Ono's R&D pipeline. The parent company's reputation in immuno-oncology, particularly around Opdivo, provides additional inbound access to emerging biotechs.

OVI is a single-LP corporate venture capital unit fully funded by Ono Pharma, operating as a division of the publicly traded pharmaceutical company rather than a traditional independent fund. This structure means OVI does not fundraise from external limited partners and is not measured against venture-style return benchmarks. Investment decisions are made on strategic-science fit with Ono's pipeline, and the firm can hold positions for extended development timelines.

OVI targets early-stage startup investments, concentrating on seed and Series A rounds, based on its stated focus on startups with cutting-edge technologies and novel therapeutic drug targets. The firm has demonstrated a willingness to follow its positions into later rounds, including a seed-extension investment in Violet Therapeutics in May 2026 and a Series B participation in Mediar Therapeutics in January 2026, when the science continues to align with Ono Pharma's R&D strategy.

OVI explicitly prioritizes three therapeutic areas that mirror Ono Pharma's internal R&D focus: oncology, immunology and inflammation, and neurology. The firm seeks to invest in startups possessing platforms or product candidates with high potential synergy to Ono's own drug-development programs. This focus excludes investment in therapeutic categories outside Ono's R&D domain, though Ono maintains a separate CVC, Ono Digital Health Investment, for healthcare-adjacent digital ventures.

Both are corporate venture capital arms of Ono Pharma, but they operate with distinct mandates. OVI focuses on early-stage biotech platform and therapeutics companies in oncology, immunology, inflammation, and neurology — areas directly aligned with Ono Pharma's R&D organization. Ono Digital Health Investment operates with a separate charter, targeting healthcare-related startups more broadly, including digital health and wellness companies that fall outside Ono's traditional pharmaceutical R&D domain.

OVI's public disclosures indicate it participates in both syndicated financings and follow-on rounds but does not specify whether it regularly takes the lead-investor role. Its January 2026 investment in Mediar Therapeutics occurred alongside an oversubscribed $76 million Series B, and its May 2026 follow-on in Violet Therapeutics was part of a $4.75 million seed extension, suggesting the firm typically invests as part of a syndicate rather than anchoring rounds as a sole lead.